cosibelimab
fortress,tg therapeutics,Checkpoint Therapeutics 
['cosibelimab', 'pivotal']
attending #asco22? checkpoint therapeutics will present results of its pivotal trial of cosibelimab in metastatic cutaneous squamous cell carcinoma (cscc) today, june 6, 2022 at 1:15pm cdt. for presentation details: $ckpt $fbio
Fortress Biotech is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. $FBIO